Danai Bem



Danai Bem is a Systematic Reviewer in the Collaborations for Leadership in Applied Health Research and Care West Midlands (CLAHRC WM) team undertaking/supporting systematic reviews for all the different themes of the program. She is also a member of the Birmingham and Brunel External Assessment Centre (BBC EAC) and works on a number of projects relating to medical technologies commissioned by NICE. 

Prior to her current role Danai has worked as a research fellow for over 10 years gaining experience in bleeding disorders, rare diseases and genetics.


  • PhD in Cancer Studies, University of Birmingham, 2008
  • BSc (Hons) in Molecular Biology, University of Dundee, 2002

Research interests

Evidence synthesis and systematic reviews (quantitative & qualitative).  Search for, review, appraise and synthesise the clinical evidence using validated systematic reviewing techniques. 

Specific interest in systematic reviews of animal studies relevant for human health.

Research Projects/Interests

  • Prevention of cardiovascular disease in primary care (e.g. prescribing oral anticoagulants for the treatment of atrial fibrillation, aspirin therapy for the prevention of cardiovascular diseases, cardiovascular mortality and morbidity in people with severe mental illness)
  • Improving health, wellbeing and parenting skills in parents of children with chronic conditions
  • Implementation/use of electronic prescribing in hospitals
  • Non-suicidal self-injury and suicidal behaviour in primary school-aged children
  • Epidemiology of rare metabolic diseases

Research previously involved

  • Rare diseases such as Arthrogryposis, Renal dysfunction and Cholestasis (ARC) syndrome (role of Vps33b/Vipar protein complex in platelet alpha granule biogenesis)
  • Mild Bleeding Disorders (former member of the Genotyping & Phenotyping of Platelets (GAPP) study group)

Willingness to take PhD students


PhD projects

Interested in supervising doctoral research students in the following areas:
• Evaluation of interventions for the prevention or treatment of cardiovascular diseases
• Rare diseases epidemiology and economic impact on healthcare system organisations